
CLAIMS

1. Use of a compound having the following Structure (II):



(II)

or a pharmaceutically acceptable salt, stereoisomer, tautomer, or prodrug thereof, in the manufacture of a medicament for the treatment, prevention, or mitigation of a migraine or symptoms related to a migraine, wherein

R^{1a} is C_1-C_6 alkyl or aryl;

R^{1b} is C_1-C_6 alkyl or aryl,

or R^{1a} and R^{1b}, together with the carbon to which they are both attached, join to form cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl;

R^2 is $–NHR^{3a}$, $–NHC(=O)R^{3b}$, $–NHC(=S)R^{3b}$, or $–C(=O)R^{3c}$;

R^{3a} is hydrogen, C_1-C_6 alkyl, or C_3-C_6 cycloalkyl, each of which is optionally substituted with one or more substituents selected from the group consisting of hydroxyl, C_3-C_6 cycloalkyl, $-NHS(O)_2CH_3$, heterocyclyl, $-C(=O)OH$, $-C(=O)N(R^{3d})R^{3d}$, or $-N(R^{3d})R^{3d}$;

R^{3b} is C_1-C_6 alkyl, C_3-C_6 cycloalkyl, or heterocyclyl each of which is optionally substituted with one or more substituents selected from the group consisting of hydroxyl, halo, C_1-C_6 alkyl, C_3-C_6 cycloalkyl, $-NHS(O)_2CH_3$, $-N(R^{3d})R^{3d}$, heterocyclyl, $-C(=O)OH$, $-C(=O)N(R^{3d})R^{3d}$, $-NHC(=O)CH_3$, $-CH_2C(=O)OH$,

R^{3c} is $-N(R^{3d})R^{3d}$ or heterocyclyl;

R^{3d} is, at each occurrence, independently hydrogen, C_1-C_6 alkyl, or C_3-C_6 cycloalkyl;

L is –NH– or $–CH_2NH–$; and

X is N and Y is CH or X is CH and Y is N.

2. The use of claim 1, wherein R^{1a} is C_1-C_6 alkyl.

3. The use of any one of claims 1-2, wherein R^{1a} is methyl.

4. The use of claim 1, wherein R^{1a} is aryl.

5. The use of claim 1, wherein R^{1a} is phenyl.

6. The use of any one of claims 1-5, wherein R^{1b} is C_1-C_6 alkyl.

7. The use of any one of claims 1-6, wherein R^{1b} is methyl.

8. The use of claim 1, wherein R^{1a} and R^{1b}, together with the carbon to which they are both attached, join to form cycloalkyl.

9. The use of claim 8, wherein the cycloalkyl is cyclopentyl or cyclohexyl.

10. The use of claim 1, wherein R^{1a} and R^{1b}, together with the carbon to which they are both attached, join to form cycloalkenyl.


11. The use of claim 10, wherein the cycloalkenyl is cyclopentenyl, cyclohexenyl, or cycloheptenyl.


12. The use of claim 1, wherein R^{1a} and R^{1b}, together with the carbon to which they are both attached, join to form heterocyclyl.


13. The use of claim 12, wherein R^{1a} and R^{1b}, together with the carbon to which they are both attached, join to form aryl.


14. The use of claim 1, wherein R^{1a} and R^{1b}, together with the carbon to which they are both attached, join to form heteroaryl.


15. The use of any one of claims 1-14, wherein the compound has one of the following structures:





;



;


;


;


;


;


or


,

or a pharmaceutically acceptable salt, stereoisomer, tautomer, or prodrug thereof, wherein

---- indicates a double or single bond;

R^4 is, at each occurrence, independently C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halo, haloalkyl, hydroxyl, -$NHS(O)_2CH_3$, or -C(O)OH,

or two R^4, together with the carbon to which they are both attached, join to form a cycloalkyl;

W is N or O;







Z is C or O; and

n is 0, 1, 2, 3, or 4.

16. The use of claim 15, wherein n is 0, 1, or 2.













17. The use of any one of claims 1-16, wherein R^2 is $–NHR^{3a}$.


18. The use of any one of claims 1-17, wherein R^2 has one of the following structures:

-NH_2;  ;  ;  ;  ;  or  .

19. The use of any one of claims 1-16, wherein R^2 is $–NHC(=O)R^{3b}$.


20. The use of claim 19, wherein R^2 has one of the following structures:

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;




21. The use of any one of claims 1-16, wherein R^2 is $–NHC(=S)R^{3b}$.

22. The use of claim 21, wherein R^2 has the following structure:







































23. The use of any one of claims 1-16, wherein R^2 is $–C(=O)R^{3c}$.

24. The use of claim 23, wherein R^2 has one of the following structures:



25. The use of any one of claims 1-24, wherein R^2 has one of the following structures:

-NH_2;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ; ;  ;  or .

26. The use of any one of claims 1-16, wherein R^2 has one of the following structures:

-NH_2 or .







27. The use of any one of claims 1-26, wherein X is CH and Y is N.








28. The use of any one of claims 1-26, wherein X is N and Y is CH.









29. The use of any one of claims 1-26, wherein L is –NH–.









30. The use of any one of claims 1-26, wherein L is $–CH_2NH–$.









31. The use of any one of claims 1-30, wherein the compound comprises one of the structures as shown hereafter:









No.	Structure
4ET-01-001	
4ET-01-002	
4ET-01-003	
4ET-01-004	
4ET-01-005	
4ET-01-010A	








4ET-01-010B	
4ET-01-014A	
4ET-01-014B	
4ET-01-021	
4ET-01-058	
4ET-02-001	
4ET-02-002	








4ET-02-003	
4ET-02-004	
4ET-02-005	
4ET-02-006	
4ET-02-007	
4ET-02-008	
4ET-02-009	
4ET-02-010	








4ET-02-011	
4ET-02-012	
4ET-02-013	
4ET-02-014	
4ET-02-015	
4ET-02-016	
4ET-02-017	
4ET-02-018	







4ET-02-019	
4ET-02-020	
4ET-02-021	
4ET-02-022	
4ET-02-023	
4ET-03-001	
4ET-03-002	
4ET-03-003	







4ET-03-004	
4ET-03-005	
4ET-03-006	
4ET-03-007	
4ET-03-008	
4ET-03-009	
4ET-03-010	
4ET-03-011	








4ET-03-012	
4ET-03-013	
4ET-03-014	
4ET-03-015	
4ET-03-016	
4ET-03-017	
4ET-03-018	








4ET-03-019	
4ET-03-020	
4ET-03-021	
4ET-03-022	
4ET-03-023	
4ET-03-024	
4ET-03-025	








4ET-03-026	
4ET-03-027	
4ET-03-028	
4ET-03-029	
4ET-03-030	
4ET-03-031	
4ET-03-032	






4ET-03-033	
4ET-03-034	
4ET-03-035	
4ET-03-036	
4ET-03-039	
4ET-03-050A	







4ET-03-050B	
4ET-03-052A	
4ET-03-052B	
4ET-03-054	
4ET-03-063	
4ET-03-066	








4ET-04-003	
4ET-04-004	
4ET-04-006	
4ET-04-010	
4ET-04-011	
4ET-04-012	
4ET-04-013	









4ET-04-014	
4ET-04-015	
4ET-04-023	
1	
2	
3	
4	








5	
6	
7	
8	
9	
10	
11	








12	
13	
14	
15	
16	







17	
18	
19	
20	
21	
22	








23	
24	
25	
26	
27	
28	
29	








30	
31	
32	
33	
34	
35	
36	
37	








38	
39	
40	
41	
42	
43	
44	







45	
46	
47	
48	
49	
50	
51	








52	
53	
54	
55	
56	
57	


58	
59	
60	
61	
62	
63	
64	

65	
66	
67	
68	
69	
70	
71	

72	
73	
74	
75	
76	
77	
78	


79	
80	
81	
82	
83	
84	

85	
86	
87	
88	
89	
90	
91	

92	



, or a pharmaceutically acceptable salt, stereoisomer, tautomer, or prodrug thereof.

32. Use of a compound having the following Structure (IV):




(IV)

or a pharmaceutically acceptable salt, hydrate, isotopic isomer, solvate, complex, stereoisomer, tautomer, or prodrug thereof, in the manufacture of a medicament for the treatment, prevention, or mitigation of a migraine or symptoms related to a migraine wherein:

Z^1 is selected from the groups consisting of  and ;

R^1 is selected from the group consisting of hydrogen, halogen, C_{1-6} alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} hydroxyalkyl, C_{3-7} branched hydroxyalkyl, cyano, C_{1-6} alkoxyl, C_{3-7} branched alkoxy, hydroxy, and C_{3-6} cycloalkyl that is optionally substituted with 1 to 3 substituents selected from the groups consisting of halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, and C_{1-6} hydroxyalkyl:

R^2 is selected from the group consisting of:



R^3 is selected from the group consisting of hydrogen, halogen, C_{1-6} alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} hydroxyalkyl, C_{3-7} branched hydroxyalkyl, cyano, C_{1-6} alkoxyl, C_{3-7} branched alkoxy , hydroxy, and C_{3-6} cycloakyl that is optionally substituted with 1 to 3 substituents selected from the groups consisting of halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, and C_{1-6} hydroxyalkyl:

R^{4a} is at each occurrence independently selected from the group consisting of hydrogen, halogen, C_{1-6} alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-7} branched haloalkyl, hydroxy, C_{1-6} alkoxyl, C_{3-7} branched alkoxy, NHCO(C_{1-6}alkyl), NHCO(C_{3-7} branched alkyl), NHCO(C_{3-7} cycloalkyl), $NHSO_2$(C_{1-6}alkyl), $NHSO_2$(C_{3-7} branched alkyl), and $NHSO_2$(C_{3-7} cycloalkyl):

R^{4b} is at each occurrence independently selected from the group consisting of hydrogen, halogen, C_{1-6} alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-7} branched haloalkyl, hydroxy, C_{1-6} alkoxyl, C_{3-7} branched alkoxy, NHCO(C_{1-6}alkyl), NHCO(C_{3-7} branched alkyl), NHCO(C_{3-7} cycloalkyl), $NHSO_2$(C_{1-6}alkyl), $NHSO_2$(C_{3-7} branched alkyl), and $NHSO_2$(C_{3-7} cycloalkyl)

R^{4c} is at each occurrence independently selected from the group consisting of hydrogen, halogen, C_{1-6} alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} hydroxyalkyl, C_{3-7} branched hydroxyalkyl, hydroxy, C_{1-6} alkoxyl, C_{3-7} branched alkoxy, NHCO(C_{1-6}alkyl), NHCO(C_{3-7} branched alkyl), NHCO(C_{3-7}

cycloalkyl), $NHSO_2(C_{1-6}alkyl)$, $NHSO_2(C_{3-7}$ branched alkyl), and $NHSO_2(C_{3-7}$ cycloalkyl)

R^{4d} is at each occurrence independently selected from the group consisting of hydrogen, halogen, C_{1-6} alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} hydroxyalkyl, C_{3-7} branched hydroxyalkyl, hydroxy, C_{1-6} alkoxyl, C_{3-7} branched alkoxy, $NHCO(C_{1-6}alkyl)$, $NHCO(C_{3-7}$ branched alkyl), $NHCO(C_{3-7}$ cycloalkyl), $NHSO_2(C_{1-6}alkyl)$, $NHSO_2(C_{3-7}$ branched alkyl), and $NHSO_2(C_{3-7}$ cycloalkyl):

R^{4e} is hydrogen, halogen, C_{1-6} alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, and C_{3-7} branched haloalkyl;

R^{4f} is hydrogen, halogen, C_{1-6} alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, and C_{3-7} branched haloalkyl;

R^{1a} and R^{1b} are taken together to form an optionally substituted 3 to 7 membered ring that optionally contains an X^1 group;


X^1 is selected from the group consisting of CF_2, $CHCO_2R^{12}$, O, NH, NR^8, and SO_2:


m is 0, 1, or 2;


n is 1, 2, or 3;


R^5 is selected from the group consisting of hydrogen, halogen, C_{1-6} alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} alkoxyl, C_{3-7} branched alkoxy, and hydroxy:







R^6 is selected from the group consisting of hydrogen, NH_2, NHR^{6a}, $NHCH_2CH_2OH$, $NHCH_2CH_2NHSO_2Me$, C_{1-6} alkoxyl, C_{3-7} branched alkoxy, and hydroxy:

R^{6a} is selected from the group consisting of -$(CO)C_{1-6}$ alkyl, -$(CO)C_{3-7}$ branched alkyl, -$(CO)C_{1-6}$ hydroxyalkyl, 

, 

, 

, 

, , , , , ,

and ;

q is 1, 2, 3, 4, 5, or 6;

e is 1, 2, 3, 4, 5, or 6;

X^2 is selected from the group consisting of hydrogen, halogen, C_{1-6}alkyl, C_{3-7} branched alkyl, C_{1-6}haloalkyl, C_{3-7} branched haloalkyl, hydroxy, C_{1-6}hydroxyalkyl, C_{3-7} branched hydroxyalkyl, C_{1-6}alkoxy, C_{3-7} branched alkoxy, C_{1-6}haloalkoxy, C_{3-7} branched haloalkoxy, NH_2, NH(C_{1-6}alkyl), N(C_{1-6}alkyl)2, C_{1-5}(COOH), C_{1-6}($NHSO_2Me$);

X^3 is selected from the group consisting of hydrogen, halogen, C_{1-5} alkyl, C_{3-7} branched alkyl, C_{1-5} haloalkyl, C_{3-7} branched haloalkyl, hydroxy, C_{1-5} hydroxyalkyl, C_{3-7} branched hydroxyalkyl, C_{1-5} alkoxy, C_{3-7} branched alkoxy, C_{1-5} haloalkoxy, C_{3-7} branched haloalkoxy, NH_2, NH(C_{1-6} alkyl), N(C_{1-6} alkyl)$_2$, COOH, C_{1-5}(COOH), $NHSO_2Me$, C_{1-5}($NHSO_2Me$);

R^7 is selected from the group consisting of hydrogen, halogen, C_{1-6} alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} alkoxyl, C_{3-7} branched alkoxy, and hydroxy:


R^8 is selected from the group consisting of C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} hydroxyalkyl, C_{3-7} branched hydroxyalkyl, C_{1-6} alkoxyl, C_{3-7} branched alkoxy, CO(C_{1-6}alkyl), CO(C_{3-7} branched alkyl), SO_2(C_{1-6}alkyl),and SO_2(C_{3-7} branched alkyl);

R^{10} is selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} alkoxyl, C_{3-7} branched alkoxy, CO(C_{1-6}alkyl), CO(C_{3-7} branched alkyl), SO_2(C_{1-6}alkyl),and SO_2(C_{3-7} branched alkyl);

R^{11} is selected from the group consisting of hydrogen and C_{1-6} alkyl;

R^{12} is selected from the group consisting of hydrogen and C_{1-6} alkyl.


33. The use of claim 32, wherein the compound has the following Structure (V):



(V)

or a pharmaceutically acceptable salt, hydrate, isotopic isomer, solvate, complex, stereoisomer, tautomer, or prodrug thereof.


34. The use of claim 32, wherein the compound has the following Structure (VI):



(VI)

or a pharmaceutically acceptable salt, hydrate, isotopic isomer, solvate, complex, stereoisomer, tautomer, or prodrug thereof.


35. The use of claim 32, wherein the compound has the following Structure (VII):



(VII)

or a pharmaceutically acceptable salt, hydrate, isotopic isomer, solvate, complex, stereoisomer, tautomer, or prodrug thereof.


36. The use of claim 32, wherein the compound has the following structure (VIII):



(VIII)

or a pharmaceutically acceptable salt, hydrate, isotopic isomer, solvate, complex, stereoisomer, tautomer, or prodrug thereof.

37. The use of claim 32, wherein the compound has the following Stucture (IX):



(IX)

or a pharmaceutically acceptable salt, hydrate, isotopic isomer, solvate, complex, stereoisomer, tautomer, or prodrug thereof, wherein:

R^{8a} is at each occurrence independently selected from the group consisting of hydrogen, halogen, C_{1-6} alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} hydroxyalkyl, C_{3-7} branched hydroxyalkyl, hydroxy, C_{1-6} alkoxyl, C_{3-7} branched alkoxy, NHCO(C_{1-6}alkyl), NHCO(C_{3-7} branched alkyl),$NHSO_2$(C_{1-6}alkyl), and $NHSO_2$(C_{3-7} branched alkyl);

R^{8b} is at each occurrence independently selected from the group consisting of hydrogen, halogen, C_{1-6} alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} hydroxyalkyl, C_{3-7} branched hydroxyalkyl, hydroxy, C_{1-6} alkoxyl, C_{3-7} branched alkoxy, NHCO(C_{1-6}alkyl), NHCO(C_{3-7} branched alkyl), $NHSO_2$(C_{1-6}alkyl), and $NHSO_2$(C_{3-7} branched alkyl);

R^{8c} is at each occurrence independently selected from the group consisting of hydrogen, halogen, C_{1-6} alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} hydroxyalkyl, C_{3-7} branched hydroxyalkyl, hydroxy, C_{1-6} alkoxyl, C_{3-7} branched alkoxy, NHCO(C_{1-6}alkyl), NHCO(C_{3-7} branched alkyl), $NHSO_2$(C_{1-6}alkyl), and $NHSO_2$(C_{3-7} branched alkyl);

R^{8d} is at each occurrence independently selected from the group consisting of hydrogen, halogen, C_{1-6} alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} hydroxyalkyl, C_{3-7} branched hydroxyalkyl, hydroxy, C_{1-6} alkoxyl, C_{3-7}

branched alkoxy, NHCO(C_{1-6}alkyl), NHCO(C_{3-7} branched alkyl), $NHSO_2$(C_{1-6}alkyl), and $NHSO_2$(C_{3-7} branched alkyl);

R^{9a} is selected from the group consisting of hydrogen, halogen, C_{1-6} alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} hydroxyalkyl, C_{3-7} branched hydroxyalkyl, hydroxy, C_{1-6} alkoxyl, and C_{3-7} branched alkoxy;


R^{9b} is selected from the group consisting of hydrogen, halogen, C_{1-6} alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} hydroxyalkyl, C_{3-7} branched hydroxyalkyl, hydroxy, C_{1-6} alkoxyl, and C_{3-7} branched alkoxy;

R^{9a} and R^{9b} are taken together to form an optionally substituted 3 to 7-membered ring;

q is 1, 2, or 3; and

z is 0, 1, or 2.

38. The use of claim 32, wherein the compound has the following Structure (X):



(X)

or a pharmaceutically acceptable salt, hydrate, isotopic isomer, solvate, complex, stereoisomer, tautomer, or prodrug thereof, wherein:

R^{8a} is at each occurrence independently selected from the group consisting of hydrogen, halogen, C_{1-6} alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} hydroxyalkyl, C_{3-7} branched hydroxyalkyl, hydroxy, C_{1-6} alkoxyl, C_{3-7}

branched alkoxy, NHCO(C_{1-6}alkyl), NHCO(C_{3-7} branched alkyl),$NHSO_2$(C_{1-6}alkyl), and $NHSO_2$(C_{3-7} branched alkyl);

R^{8b} is at each occurrence independently selected from the group consisting of hydrogen, halogen, C_{1-6} alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} hydroxyalkyl, C_{3-7} branched hydroxyalkyl, hydroxy, C_{1-6} alkoxyl, C_{3-7} branched alkoxy, NHCO(C_{1-6}alkyl), NHCO(C_{3-7} branched alkyl), $NHSO_2$(C_{1-6}alkyl), and $NHSO_2$(C_{3-7} branched alkyl);

R^{8c} is at each occurrence independently selected from the group consisting of hydrogen, halogen, C_{1-6} alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} hydroxyalkyl, C_{3-7} branched hydroxyalkyl, hydroxy, C_{1-6} alkoxyl, C_{3-7} branched alkoxy, NHCO(C_{1-6}alkyl), NHCO(C_{3-7} branched alkyl), $NHSO_2$(C_{1-6}alkyl), and $NHSO_2$(C_{3-7} branched alkyl);

R^{8d} is at each occurrence independently selected from the group consisting of hydrogen, halogen, C_{1-6} alkyl, C_{3-7} branched alkyl, C_{1-6} haloalkyl, C_{3-7} branched haloalkyl, C_{1-6} hydroxyalkyl, C_{3-7} branched hydroxyalkyl, hydroxy, C_{1-6} alkoxyl, C_{3-7} branched alkoxy, NHCO(C_{1-6}alkyl), NHCO(C_{3-7} branched alkyl), $NHSO_2$(C_{1-6}alkyl), and $NHSO_2$(C_{3-7} branched alkyl); q is 1, 2, or 3; and

z is 0, 1, or 2.

39. The use of claim 32, wherein the compound is:

N-(6-((8"-methyl-1",5"-dioxo-1",5"-dihydro-2"*H*-dispiro[cyclopropane-1,1'-cyclohexane-3',3"-imidazo[1,5-*a*]pyridin]-6"-yl)amino)pyrimidin-4-yl)cyclopropanecarboxamide;

6"-((6-Aminopyrimidin-4-yl)amino)-8"-methyl-2"*H*-dispiro[cyclopropane-1,1'-cyclohexane-3',3"-imidazo[1,5-*a*]pyridine]-1",5"-dione;

N-(6-((8"-methyl-1",5"-dioxo-1",5"-dihydro-2"H-dispiro[cyclopropane-1,1'-cyclohexane-4',3"-imidazo[1,5-a]pyridin]-6"-yl)amino)pyrimidin-4-yl)cyclopropanecarboxamide;

N-(6-((8"-methyl-1",5"-dioxo-1",5"-dihydro-2"H-dispiro[aziridine-2,1'-cyclohexane-4',3"-imidazo[1,5-a]pyridin]-6"-yl)amino)pyrimidin-4-yl)cyclopropanecarboxamide;

N-(6-((8"-methyl-1",5"-dioxo-1",5"-dihydro-2"H-dispiro[cyclobutane-1,1'-cyclobutane-3',3"-imidazo[1,5-a]pyridin]-6"-yl)amino)pyrimidin-4-yl)cyclopropanecarboxamide;

N-(6-((8"-methyl-1",5"-dioxo-1-(2-oxo-2-phenyl-1l2-ethyl)-1",5"-dihydro-2"H-dispiro[aziridine-2,1'-cyclohexane-4',3"-imidazo[1,5-a]pyridin]-6"-yl)amino)pyrimidin-4-yl)cyclopropanecarboxamide;

tert-butyl 6"-((6-(cyclopropanecarboxamido)pyrimidin-4-yl)amino)-8"-methyl-1",5"-dioxo-1",5"-dihydro-2"H-dispiro[azetidine-3,1'-cyclohexane-4',3"-imidazo[1,5-a]pyridine]-1-carboxylate;

N-(6-((8"-methyl-1",5"-dioxo-1",5"-dihydro-2"H-dispiro[azetidine-3,1'-cyclohexane-4',3"-imidazo[1,5-a]pyridin]-6"-yl)amino)pyrimidin-4-yl)cyclopropanecarboxamide;

6"-((6-((2-hydroxyethyl)amino)pyrimidin-4-yl)amino)-8"-methyl-2"H-dispiro[cyclopropane-1,1'-cyclohexane-4',3"-imidazo[1,5-a]pyridine]-1",5"-dione;

6"-((6-Aminopyrimidin-4-yl)amino)-8"-methyl-2"*H*-dispiro[cyclopropane-1,1'-cyclohexane-4',3"-imidazo[1,5-*a*]pyridine]-1",5"-dione;

6"-((6-aminopyrimidin-4-yl)amino)-8"-methyl-1-(2-oxo-2-phenyl-1l2-ethyl)-2"H-dispiro[aziridine-2,1'-cyclohexane-4',3"-imidazo[1,5-a]pyridine]-1",5"-dione;

1-(aminomethyl)-*N*-(6-((8"-methyl-1",5"-dioxo-1",5"-dihydro-2"H-dispiro[cyclopropane-1,1'-cyclohexane-4',3"-imidazo[1,5-a]pyridin]-6"-yl)amino)pyrimidin-4-yl)cyclopropane-1-carboxamide;

(1R,5S,6R)-*N*-(6-((8"-methyl-1",5"-dioxo-1",5"-dihydro-2"H-dispiro[cyclopropane-1,1'-cyclohexane-4',3"-imidazo[1,5-a]pyridin]-6"-yl)amino)pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide;

N-(6-((8"-methyl-1",5"-dioxo-1",5"-dihydro-2"H-dispiro[cyclopropane-1,1'-cyclohexane-4',3"-imidazo[1,5-a]pyridin]-6"-yl)amino)pyrimidin-4-yl)-2-azaspiro[3.3]heptane-6-carboxamide;

2-methyl-*N*-(6-((8"-methyl-1",5"-dioxo-1",5"-dihydro-2"H-dispiro[cyclopropane-1,1'-cyclohexane-4',3"-imidazo[1,5-a]pyridin]-6"-yl)amino)pyrimidin-4-yl)-2-azaspiro[3.3]heptane-6-carboxamide;

(1R,5S,6R)-3-methyl-N-(6-((8"-methyl-1",5"-dioxo-1",5"-dihydro-2"H-dispiro[cyclopropane-1,1'-cyclohexane-4',3"-imidazo[1,5-a]pyridin]-6"-yl)amino)pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide;

N-(6-((8"-methyl-1",5"-dioxo-1",5"-dihydro-2"H-dispiro[cyclopropane-1,1'-cyclohexane-4',3"-imidazo[1,5-a]pyridin]-6"-yl)amino)pyrimidin-4-yl)-1-(methylsulfonamido methyl)cyclopropane-1-carboxamide;

1-((dimethylamino)methyl)-N-(6-((8"-methyl-1",5"-dioxo-1",5"-dihydro-2"H-dispiro[cyclopropane-1,1'-cyclohexane-4',3"-imidazo[1,5-a]pyridin]-6"-yl)amino)pyrimidin-4-yl)cyclopropane-1-carboxamide;

6"-((6-aminopyrimidin-4-yl)amino)-8"-methyl-2"H-dispiro[cyclobutane-1,1'-cyclobutane-3',3"-imidazo[1,5-a]pyridine]-1",5"-dione;

6"-((6-aminopyrimidin-4-yl)amino)-8"-methyl-2"H-dispiro[aziridine-2,1'-cyclohexane-4',3"-imidazo[1,5-a]pyridine]-1",5"-dione;

6"-((6-aminopyrimidin-4-yl)amino)-8"-methyl-2"H-dispiro[cyclopropane -1,1'-cyclopentane-3',3"-imidazo[1,5-a]pyridine]-1",5"-dione;

6"-((6-aminopyrimidin-4-yl)amino)-8"-methyl-2"H-dispiro[cyclopentane-1,1'-cyclopentane-3',3"-imidazo[1,5-a]pyridine]-1",5"-dione;

6"-((6-aminopyrimidin-4-yl)amino)-3,3-difluoro-8"-methyl-2"H-dispiro[cyclobutane-1,1'-cyclobutane-3',3"-imidazo[1,5-a]pyridine]-1",5"-dione;

6"-((6-aminopyrimidin-4-yl)amino)-8"-methyl-2"H-dispiro[cyclopentane-1,1'-cyclobutane-3',3"-imidazo[1,5-a]pyridine]-1",5"-dione;

6"-((6-aminopyrimidin-4-yl)amino)-8"-methyl-2"H-dispiro[cyclobutane-1,1'-cyclohexane-4',3"-imidazo[1,5-a]pyridine]-1",5"-dione;

6"-((6-aminopyrimidin-4-yl)amino)-8"-methyl-2"H-dispiro[cyclohexane-1,1'-cyclobutane-3',3"-imidazo[1,5-a]pyridine]-1",5"-dione;

ethyl 6"-((6-(cyclopropanecarboxamido)pyrimidin-4-yl)amino)-8"-methyl-1",5"-dioxo-1",5"-dihydro-2"H-dispiro[cyclopropane-1,1'-cyclohexane-4',3"-imidazo[1,5-a]pyridine]-2-carboxylate;

tert-butyl (6"-((6-(cyclopropanecarboxamido)pyrimidin-4-yl)amino)-8"-methyl-1",5"-dioxo-1",5"-dihydro-2"H-dispiro[cyclopropane-1,1'-cyclohexane-4',3"-imidazo[1,5-a]pyridin]-2-yl)carbamate;

N-(6-((2,2-difluoro-8"-methyl-1",5"-dioxo-1",5"-dihydro-2"H-dispiro[cyclopropane-1,1'-cyclohexane-4',3"-imidazo[1,5-a]pyridin]-6"-yl)amino)pyrimidin-4-yl)cyclopropanecarboxamide;

6"-((6-aminopyrimidin-4-yl)amino)-2,2-difluoro-8"-methyl-2"H-dispiro[cyclopropane-1,1'-cyclohexane-4',3"-imidazo[1,5-a]pyridine]-1",5"-dione;

6"-((6-Aminopyrimidin-4-yl)amino)-8"-methyl-2"*H*-dispiro[cyclopropane-1,1'-cycloheptane-4',3"-imidazo[1,5-*a*]pyridine]-1",5"-dione;

6"-((6-Aminopyrimidin-4-yl)amino)-8"-methyl-2"*H*-dispiro[cyclopropane-1,1'-cyclohexane-4',3"-imidazo[1,5-*a*]pyridin]-2'-ene-1",5"-dione,

or a pharmaceutically acceptable salt, hydrate, isotopic isomer, solvate, complex, stereoisomer, tautomer, or prodrug thereof.